A MESSAGE FROM WHA PRESIDENT, DR SU WANG

As we enter 2021, we are now in the ‘decade of elimination’. Over the next ten years, countries need to accelerate efforts to eliminate viral hepatitis by 2030. Yet, we know that most countries are not on track to reach the 2030 goals set out by the World Health Organization. The COVID-19 pandemic has also hampered progress. In 2021 it is clear that a concerted effort is needed to raise the voices of the communities affected by viral hepatitis and to advocate for more support for hepatitis programmes especially in the face of the COVID-19 pandemic.
 
The World Hepatitis Alliance (WHA) and our members will be at the forefront of the global advocacy movement, exploring every opportunity to increase support for hepatitis programmes and raise awareness of viral hepatitis. Our organisation enters the new year with added strength in our new president-elect, Danjuma Adda from Nigeria, who will work alongside me this year before taking over as president in 2022.
 
WHA will be busy this year, we will be continuing to call on global funders to join the fight against hepatitis to support low-and-middle-income countries to eliminate hepatitis. We will be looking to raise the voices of the communities and people affected by viral hepatitis, highlighting the human impact of hepatitis. There will also be a new capacity-building programme launched during this year which aims to work with members to support their advocacy work. In July, we will be raising awareness on World Hepatitis Day and we will be launching a new theme for the day soon. We are also aiming to host the third World Hepatitis Summit towards the end of 2021 where we hope to bring together the global hepatitis community.
 
There is much work to be done, and the strength of WHA is in our members. I know many of you face uncertain times, and we will be advocating at the highest levels for more support for your organisations.
 
Throughout my time with WHA I have been inspired by the determination and resilience of our members. Our collective strength and voices combined are an unstoppable force, and I look forward to working with you this year to make the elimination of hepatitis a reality.
 
Wishing you a happy new year,
 
Su Wang, MD MPH
President

Latest News

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close